Drug Trial Radar · NCT06715670
A Study to Investigate the Blood Concentrations of 4 Different Oral Doses of Zibotentan in Healthy Non-Asian and Japanese Participants
Last checked: Nov 20, 2026Latest source record: Dec 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
30
Actual
Start
Dec 5, 2024
Primary completion
Feb 28, 2025
Study completion Feb 28, 2025
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- Collaborators
- Parexel
- First posted
- Dec 4, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study aim to assess the Pharmacokinetics of Zibotentan in Healthy Non-Asian and Japanese Participants.
Conditions
- Liver Cirrhosis
Interventions
ZibotentanDrug
Participant will receive 4 different single doses of zibotentan on Day 1 of each treatment period orally.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Area under concentration-time curve from time 0 to infinity (AUCinf)Time frame: Day 1 through Day 3 of each Treatment Period (each Treatment Period is 7 days)
- Area under concentration-curve from time 0 to the last quantifiable concentration (AUClast)Time frame: Day 1 through Day 3 of each Treatment Period (each Treatment Period is 7 days)
- Maximum observed drug concentration (Cmax)Time frame: Day 1 through Day 3 of each Treatment Period (each Treatment Period is 7 days)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Research Site
Glendale, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.